<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Frontiers in Genetics | New and Recent Articles</title>
        <link>https://www.frontiersin.org/journals/genetics</link>
        <description>RSS Feed for Frontiers in Genetics | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-10-19T02:51:34.509+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1910504</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1910504</link>
        <title><![CDATA[Recent achievements of the National Center Biobank Network (NCBN) bioresources through Japanese fiscal year 2025]]></title>
        <pubdate>2026-10-19T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Yosuke Omae</author><author>Katsushi Tokunaga</author>
        <description><![CDATA[The National Center Biobank Network (NCBN) is constituted by a network of biobanks from five National Centers and the Japan Institute for Health Security (JIHS). The NCBN primarily collects samples from patients with various diseases, amassing a total of more than 250,000 participants and 800,000 human biospecimens as of the end of March 2026. The primary sample types are blood and DNA, with spinal fluid and frozen tissue samples also collected depending on the characteristics of the disease. These samples are accompanied by highly specialized and traceable clinical information supported by advanced medical care and expertise. Moreover, some samples are accompanied by whole-genome sequencing data. Consequently, these resources provide a unique platform for translational research, biomarker discovery, and genomic medicine in Japan. In the present review, we provide a detailed account of the recent achievements of NCBN biobanks and their biospecimens and genomic data.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1900040</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1900040</link>
        <title><![CDATA[Genetic associations in the gut–lung axis: a Mendelian randomization study and in vitro assessment of sodium butyrate in non-small cell lung cancer]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Weili Yi</author><author>Li Qin</author><author>Dongning Huang</author><author>Fang Wu</author>
        <description><![CDATA[BackgroundThe gut microbiota may influence host immunity, but the relationship between specific microbial genera and non-small cell lung cancer (NSCLC) risk remains uncertain. We evaluated genetically proxied microbial abundance and conducted separate exploratory experiments with sodium butyrate (NaB).MethodsTwo-sample Mendelian randomization (MR) used genus-level MiBioGen summary statistics and FinnGen/OpenGWAS NSCLC data (finn-b-C3_LUNG_NONSMALL; 1,627 cases and 217,165 controls). Instruments were selected at P < 1 × 10−5 with linkage disequilibrium clumping (r2 < 0.001; 10,000 kb) and F > 10. Inverse variance weighting (IVW) was the primary estimator; Benjamini–Hochberg false discovery rate (BH-FDR) correction was applied across 119 genera. Sensitivity analyses included MR-Egger, weighted median, mode-based methods, heterogeneity, pleiotropy and leave-one-out analyses. NaB, used as a representative microbial metabolite rather than a taxon-specific product, was evaluated at 1 mM for 24 h in tumor-conditioned medium (TCM) experiments.ResultsSix genera showed nominal inverse IVW associations with NSCLC risk (P = 0.0120–0.0498): Alistipes, Methanobrevibacter, Bacteroides, Ruminococcus gauvreauii group, Ruminococcus 1 and Peptococcus. None survived BH-FDR correction (q = 0.6072–0.9819). Sensitivity tests did not detect heterogeneity or directional pleiotropy for these genera, but alternative estimators and leave-one-out analyses did not consistently retain nominal significance. In THP-1-derived macrophages, NaB treatment altered polarization-associated transcripts, reduced the TCM-associated CCK-8 signal and increased acetylated histone H3 (Ac-H3) relative to TCM alone.ConclusionThe MR analysis identifies six suggestive microbial associations with NSCLC risk that require independent replication. Complementary NaB experiments show changes in macrophage-associated transcripts, metabolic viability and histone acetylation, providing a basis for further study of microbial metabolites in the tumor microenvironment.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1927885</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1927885</link>
        <title><![CDATA[Single-cell and bulk transcriptomic characterization of the osteosarcoma microenvironment reveals lineage-specific programs and inflammatory differences associated with metastasis]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Zhiwen Zhou</author><author>Zhijun Li</author>
        <description><![CDATA[BackgroundOsteosarcoma is a heterogeneous bone malignancy in which malignant, immune, stromal, and bone-lineage cells form a complex microenvironment. Clinical activity of immune-checkpoint blockade has remained limited in advanced osteosarcoma, motivating cell-type-resolved investigation of the tumor microenvironment while avoiding mechanistic overinterpretation of cross-sectional transcriptomic data.MethodsSingle-cell RNA-sequencing data from primary osteosarcoma were obtained from GEO (GSE162454; six patients) and analyzed with Scanpy using quality filtering, normalization, highly variable gene selection, principal component analysis, neighborhood graph construction, UMAP, Leiden clustering, and marker-based cell-type annotation. Seven transcriptional programs and ligand-receptor communication scores were evaluated. An independent bulk osteosarcoma cohort with metastatic status and overall survival annotation (GSE21257; n = 53) was used for differential expression, cross-platform comparison, and survival analysis. RT-qPCR was performed in primary human osteoblasts exposed to MG-63 osteosarcoma-conditioned medium.ResultsAfter quality control, 44,189 cells with 25,473 detected genes were retained. Leiden clustering resolved 23 clusters annotated into 11 cell types; myeloid cells (34.0%) and osteoblasts (16.6%) were the largest populations. Osteoblasts showed the highest osteogenic program scores, whereas myeloid cells showed the highest inflammatory and immune-evasion scores. Reclustering of osteoblasts, osteocytes, and mesenchymal stromal cells resolved seven stromal subclusters, but pairwise co-expression between representative osteogenic and inflammatory genes was generally weak. Ligand-receptor analysis highlighted MIF-CD74, SPP1-CD44, and SPP1-ITGAV as the strongest scored interactions. In GSE21257, 333 genes differed between metastatic and non-metastatic tumors at FDR<0.05; the inflammatory module was lower in metastatic tumors, whereas the osteogenic module was not significantly different. The single-cell osteoblast effect showed only modest concordance with the bulk metastatic effect (Spearman rho = 0.254), and a 20-gene osteoblast signature did not stratify overall survival (log-rank p = 0.968). In vitro, osteosarcoma-conditioned medium reduced RUNX2 and SP7 and increased SOST and RANKL expression in primary osteoblasts.ConclusionIntegrated single-cell and bulk transcriptomic analyses identify lineage-specific osteogenic, inflammatory, and communication programs in osteosarcoma but also demonstrate limited cross-platform generalizability of osteoblast-centered signatures. The RT-qPCR experiment supports an osteoblast transcriptional response to soluble factors from MG-63 cells, but it does not establish a specific immunosuppressive mechanism or prognostic biomarker. These findings should therefore be considered hypothesis-generating and require independent single-cell, spatial, and functional validation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1972696</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1972696</link>
        <title><![CDATA[Causal associations between gut microbiota and autism spectrum disorder and attention-deficit/hyperactivity disorder: a two-sample mendelian randomization study]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Brief Research Report</category>
        <author>Shangyun Shi</author><author>Ancha Baranova</author><author>Hongbao Cao</author><author>Fuquan Zhang</author>
        <description><![CDATA[BackgroundThe gut microbiota have been implicated in the development of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). However, the precise causal relationships between the gut microbiota and ASD or ADHD remain unclear.MethodsWe investigated potential causal associations between gut microbiota and two neurodevelopmental mental disorders (ASD and ADHD) via Mendelian randomization (MR) analyses. We used genome-wide association study (GWAS) summary datasets, including data from the MiBioGen consortium (N = 18,340), the Dutch Microbiome Project (N = 8,208), an ASD GWAS (N = 46,350), and an ADHD GWAS (N = 292,548).ResultsOur MR analysis identified 16 gut bacterial taxa associated with ASD. Seven taxa were associated with an increased risk (OR 1.03–1.10), while nine were associated with a decreased risk (OR 0.89–0.96). Conversely, 28 gut bacterial taxa were causally linked to ADHD: 16 were associated with an increased risk (OR 1.02–1.04), and 12 were associated with a decreased risk (OR 0.95–0.98). Both ASD and ADHD were causally influenced by the family “Clostridiales noname,” but with opposite effects.ConclusionOur MR analysis revealed causal effects of specific gut microbiota on ASD and ADHD, suggesting that certain gut microbes may play a role in the development and treatment of these disorders, as well as in their differential diagnosis.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1899397</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1899397</link>
        <title><![CDATA[Genotype distribution and identification of rare variants in α/β-thalassemia in chengdu: including the first report of HBA1:c.300+48C > G]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Xiaohua Liu</author><author>Hongfei Du</author><author>Linyan Zhang</author><author>Yang Yu</author><author>Guixiang Wang</author><author>Xing He</author><author>Huacui Huang</author><author>Ying Xu</author>
        <description><![CDATA[ObjectiveThalassemia is among the most common inherited diseases worldwide. We aimed to analyze the genotype and frequency distribution of thalassemia in a general hospital in Chengdu and provide a reference for genetic counseling and prenatal diagnosis.MethodsA total of 6,357 subjects referred to Xindu District People’s Hospital of Chengdu for thalassemia screening between June 2021 and December 2025 were collected. Thalassemia genotypes were tested using polymerase chain reaction (PCR), flow-through hybridization technology and Sanger sequencing analyses.ResultsA total of 793 subjects heterozygous or homozygous for alpha/beta-globin mutations were detected from 6,357 blood samples, including 480 α-thalassemia variants, 291 β-thalassemia variants, and 22 cases with concurrent α and β-thalassemia variants. One novel variant, HBA1:c.300 + 48C > G, and was not detected in the IthaGenes, HbVar, dbSNP, Pubmed, and HGMD databases.ConclusionThe genotype distribution of thalassemia in a general hospital in Chengdu is complex and heterogeneous. The novel HBA1 variant was identified in a patient with severe anemia; however, its functional impact and clinical significance require further investigation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1904219</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1904219</link>
        <title><![CDATA[Adult presentation of SLC29A3-related disorder spectrum with marked hypogammaglobulinemia due to a recurrent homozygous pathogenic variant (G437R): a case report]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Case Report</category>
        <author>Mohammad Ameen Ishqair</author><author>Abbas K. H. Masalma</author><author>Mohanad Saleh</author><author>Fawaz Awad</author><author>Aliaa Khalili</author><author>Anas Ameen Ishqair</author><author>Somaya Salah</author><author>Abed-Rahman N. Saleh</author>
        <description><![CDATA[BackgroundSLC29A3-related disorder spectrum encompasses rare autosomal recessive conditions characterized by multisystem involvement, including immunodeficiency, lymphoproliferation, cutaneous findings, endocrine dysfunction, and growth failure. The clinical presentation is highly heterogeneous, often leading to delayed diagnosis, particularly in adults.Case presentationA 33-year-old Palestinian woman born to consanguineous parents presented with a lifelong history of recurrent severe respiratory infections, growth failure (short stature and microcephaly), recurrent nephrolithiasis, chronic vomiting, generalized hirsutism, and bilateral hallux valgus. Laboratory evaluation revealed marked hypogammaglobulinemia (IgG <320 mg/dL, IgA <25 mg/dL, IgM <25 mg/dL), microcytic anemia, and severe vitamin D deficiency. Imaging confirmed chronic pulmonary small-airway changes and a chronically small right kidney with recurrent stones. Whole-exome sequencing identified a homozygous pathogenic SLC29A3 variant (c.1309G>A; p.Gly437Arg), establishing a diagnosis within the SLC29A3-related disorder spectrum. This case is unique due to its adult presentation, the exceptional severity of the humoral immunodeficiency, and the associated renal manifestations, which are infrequently reported in this spectrum.ConclusionThis report underscores the importance of considering SLC29A3-related disorder spectrum in adults with multisystem disease. Recognition of this spectrum enables targeted multidisciplinary care, including immunoglobulin replacement therapy and anticipatory surveillance for endocrine and renal complications.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1947419</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1947419</link>
        <title><![CDATA[Clinically relevant chromosomal abnormalities and chromosomal polymorphisms in 7,530 patients undergoing reproductive genetic counseling: a retrospective cytogenetic study in a Chinese Han population]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Songhang Wu</author><author>Hongyan Shang</author><author>Wenhua Wang</author><author>Dan Chen</author><author>Wennan Wu</author>
        <description><![CDATA[BackgroundChromosomal aberrations are important causes of reproductive disorders, but their clinical interpretation is often complicated by the presence of benign chromosomal polymorphisms that may obscure the true diagnostic yield of karyotyping. The aim of this study was to evaluate peripheral blood karyotyping in patients undergoing reproductive genetic counseling and to distinguish clinically relevant chromosomal abnormalities from chromosomal polymorphisms.MethodsA total of 7,530 patients who visited the reproductive center and the obstetrics and gynecology genetic clinic of the First Affiliated Hospital of Fujian Medical University from January 2016 to December 2022 were included. Peripheral blood karyotyping was performed using lymphocyte culture, routine chromosome preparation, and G-banding. Cytogenetic findings were classified into clinically relevant chromosomal abnormalities and chromosomal polymorphisms. Chromosomal polymorphisms were analyzed separately and were not counted as the primary diagnostic outcome. Correspondence analysis was performed using an observed-count matrix linking major clinical manifestations with representative karyotypic findings.ResultsA total of 552 abnormal cytogenetic findings were detected, corresponding to an overall cytogenetic finding rate of 7.33% (552/7,530). Among them, 246 cases were classified as clinically relevant chromosomal abnormalities, giving a primary diagnostic rate of 3.27% (246/7,530), whereas 306 cases were chromosomal polymorphisms, accounting for 4.06% of the total cohort and 55.43% of all abnormal cytogenetic findings. In correspondence analysis, the first two dimensions explained 77.9% and 15.2% of the total inertia, respectively. The global chi-square test indicated a non-random association between clinical manifestations and representative karyotypic findings (chi-square = 69.92, df = 16, P < 0.001).ConclusionPeripheral blood karyotyping remains a useful first-line cytogenetic test in reproductive genetic counseling. Clinically relevant chromosomal abnormalities and chromosomal polymorphisms should be reported and interpreted separately. Phenotype-guided interpretation may improve the clinical value of karyotyping and help identify patients who require additional molecular confirmation or multidisciplinary counseling.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1953975</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1953975</link>
        <title><![CDATA[Biobanking across Africa: from participant-level trust to institutional trustworthiness]]></title>
        <pubdate>2026-10-16T00:00:00Z</pubdate>
        <category>Perspective</category>
        <author>Aisha Sallah</author><author>Salma Tarmoun</author><author>Krishna Gajjar</author><author>Patience Yeboah</author><author>Bernard Abakah</author><author>Everlyne Mutua</author><author>Dimitris Boufidis</author>
        <description><![CDATA[Building trust and maintaining participant engagement are widely recognized as requirements for sustainable biobanking. Yet efforts to achieve these goals must account for the historical, economic, geo-political and socio-cultural contexts that shape participant engagement. In Africa, biobanking has shown immense scientific and global public health value, but persistent governance challenges continue to affect participation. In this Perspective, we examine the factors that have constrained participant engagement in biobanking across Africa. We argue that trust is not simply a participant-level deficit to be corrected through increased outreach. Instead, trust and mistrust are shaped by the broader biobanking ecosystem, and by whether its institutions have demonstrated that they are worthy of public trust. Drawing on studies from across the continent, we propose strategies for how governance bodies, researchers and healthcare professionals can develop biobanking systems and frameworks that are sustainable and accountable to the public at both the national and international levels. Importantly, we identify science diplomacy as a valuable mechanism for strengthening cross-border coordination in support of more equitable, coherent and locally-governed biobanking initiatives.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1935109</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1935109</link>
        <title><![CDATA[Case Report: Prenatal diagnosis and genetic counseling for a homozygous segment spanning chromosome 6q25.3q27 with normal phenotype]]></title>
        <pubdate>2026-10-15T00:00:00Z</pubdate>
        <category>Case Report</category>
        <author>Dandan Li</author><author>Jie Hu</author><author>Ji Wu</author><author>Xuna Bian</author>
        <description><![CDATA[BackgroundRuns of Homozygosity (ROH) are long, uninterrupted stretches of the genome in which an individual is homozygous at virtually every assayed variant. Uniparental disomy (UPD) is an epigenetic anomaly in which both copies, or a portion of a pair of homologous chromosomes, are inherited from one parent.Materials and MethodsA 29-year-old gravida 2, para 1 woman underwent amniocentesis at 18 weeks’ gestation because non-invasive prenatal testing (NIPT) indicated a high probability of chromosome 11 gain. GTG-banding karyotype analysis was performed on cultured amniocytes. Chromosomal microarray analysis (CMA), whole-exome sequencing (WES) on uncultured amniocytes were performed.ResultsCMA detected a copy-neutral 10.42 Mb ROH of chromosome 6, arr [GRCh37] 6q25.3q27 (157,776,570_168,194,615)x2 hmz. Trio-WES confirmed that the homozygous 6q25.3q27 segment resulted from biparental inheritance. Across the 10.42 Mb interval, multiple informative SNPs showed that the fetal homozygous genotypes were compatible with the contribution of one allele from each parent, and no informative single-nucleotide polymorphism (SNP) showed fetal homozygosity with one parent being wild-type for the fetal allele, thus excluding segmental uniparental disomy. At the 6-month checkup, the baby was developing normally.ConclusionWe provide a detailed description of a homozygous segment spanning chromosome 6q25.3q27 with normal phenotype. Combination of NIPT, prenatal ultrasound, karyotype analysis, CMA, WES and genetic counseling will prove a more accurate risk assessment for the prenatal diagnosis of ROH and UPD.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.2000967</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.2000967</link>
        <title><![CDATA[Editorial: Advanced genetic and genomic methods and applications for malaria surveillance]]></title>
        <pubdate>2026-10-15T00:00:00Z</pubdate>
        <category>Editorial</category>
        <author>Shazia Ruybal-Pesántez</author><author>Johanna H. Kattenberg</author><author>Anita Ghansah</author><author>Sarah Auburn</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1812905</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1812905</link>
        <title><![CDATA[Revisiting the genetic support of leukotriene pathway drug targets in atherosclerotic cardiovascular disease]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Tristan St-Laurent</author><author>Julien St-Pierre</author><author>Julien Quang Le Van</author><author>Marc-André Legault</author>
        <description><![CDATA[Arachidonate 5-lipoxygenase (5-LO) and its activating protein, encoded by ALOX5 and ALOX5AP respectively, are two leukotriene pathway proteins suspected to play a role in atherosclerotic cardiovascular disease (ASCVD) through inflammatory mechanisms. Prior genetic association studies linking ALOX5 and ALOX5AP to ASCVD have motivated clinical trials of 5-LO inhibitors, such as atreleuton, which was associated with reduced atherosclerotic plaque progression in patients with a recent acute coronary syndrome in a phase II trial. However, the effect of 5-LO inhibition on ASCVD clinical outcomes remains unclear. Using data from the UK Biobank, we revisit previously reported genetic associations of ALOX5 and ALOX5AP with ASCVD using a multi-ancestry meta-analysis including data from 378,962 participants. We characterize ancestral differences in previously studied ALOX5 and ALOX5AP polymorphisms which could have led to population stratification. When adequately accounting for ancestry, these previous associations were not replicated. In addition to our replication efforts, we used association scans and transcriptome-wide association studies to test the involvement of leukotriene pathway genes with ASCVD. Overall, our results do not support a role for genetic variation in ALOX5 or its activating protein in ASCVD risk.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1998945</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1998945</link>
        <title><![CDATA[Correction: Tumor-immune microenvironment and nutritional status biomarkers predict recurrence after total colectomy for locally advanced colon cancer: development and internal validation of a nomogram]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Yanhui Yang</author><author>Meng Gao</author><author>Songchun Liu</author><author>Qiong Yang</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1894027</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1894027</link>
        <title><![CDATA[Machine learning, molecular docking, and experimental validation identify shared molecular signatures between idiopathic pulmonary arterial hypertension and malignant pleural mesothelioma: a retrospective study]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Neng Zhang</author><author>Chunyu Wang</author><author>Rui Wang</author><author>Xue Guo</author><author>Jing Yu</author><author>Jie Wang</author><author>Qin Luo</author><author>Yun Wu</author>
        <description><![CDATA[BackgroundIdiopathic pulmonary arterial hypertension (IPAH) exhibits cancer-like features, yet its pathogenesis remains unclear. Given molecular similarities between IPAH and malignant pleural mesothelioma (MPM), this study aimed to uncover shared transcriptomic patterns.MethodsGEO datasets for IPAH and MPM were analyzed. Overlapping DEGs and WGCNA modules were identified. PPI network analysis combined with LASSO, random forest, and SVM-RFE was used to identify candidate biomarker genes. A classification model was constructed and evaluated using leave-one-out cross-validation and bootstrap optimism correction. Immune infiltration was evaluated by ssGSEA. Molecular docking and MD simulations assessed drug binding to candidate target proteins. qRT-PCR validated candidate biomarker gene expression.ResultsSix concordantly upregulated and eleven concordantly downregulated DEGs were shared between IPAH and MPM. Upregulated genes were enriched in cell cycle regulation, while downregulated genes were enriched in neutrophil chemotaxis. WGCNA identified 58 overlapping genes. CXCR2, S100A9, and LCN2 were identified as candidate biomarker genes. A ROTS sensitivity analysis confirmed that all 1710 MPM DEGs were reproducible and directionally concordant at the matching FDR <0.05 threshold despite the imbalanced case–control ratio. The classification model achieved AUCs of 0.909 and 0.875 in training and external validation sets, with a LOOCV AUC of 0.879 and an optimism-corrected AUC of 0.896. Immune infiltration revealed increased Th17 cells but decreased neutrophils in IPAH. CXCR2 and S100A9 expression correlated with neutrophil infiltration; LCN2 expression correlated with metabolic reprogramming. Navarixin showed the strongest binding affinity to CXCR2 (−10.1 kcal/mol). MD simulations confirmed stable binding of the CXCR2-Navarixin complex. qRT-PCR confirmed significant downregulation of all three genes in IPAH patients.ConclusionThis hypothesis-generating study identifies shared transcriptomic signatures between IPAH and MPM, highlighting CXCR2, S100A9, and LCN2 as candidate biomarkers linked to immune dysregulation and metabolic reprogramming. The computational and correlative nature of these findings, together with the limited size of the external validation cohort, requires confirmation through functional experiments and validation in larger, independent, and multicentre cohorts before clinical translation can be considered.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1904151</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1904151</link>
        <title><![CDATA[Overexpression of centromere-localized IFIT3 impairs mitochondrial function and disrupts cellular proliferation and cell cycle progression in down syndrome]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Peng Zhou</author><author>Yanna Liu</author><author>Caixia Lei</author><author>Fanyi Zeng</author><author>Jing-bin Yan</author>
        <description><![CDATA[BackgroundDown syndrome (DS, trisomy 21) is the most prevalent human autosomal aneuploidy, driven by non-disjunction of chromosome 21 during maternal gametogenesis. Centromere-kinetochore complexes mediate accurate chromosome segregation, and centromeric protein dysregulation is linked to chromosome instability; nevertheless, how perturbations of centromere-proximal proteins drive cellular pathogenesis in DS remain poorly defined.MethodsWe applied CENPA-GFP-APEX2 proximity labeling coupled with LC-MS/MS quantitative proteomics to systematically profile CENPA-proximal proteins in euploid normal amniocytes (NACs) and trisomy 21 DS-derived amniocytes (DSACs). Differentially abundant candidate proteins (DAPs) were biochemically validated by Western blot, followed by bioinformatic enrichment analyses. The top upregulated candidate Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) was overexpressed in human induced pluripotent stem cells (hiPSCs) to dissect its functional impacts on DS-relevant cellular phenotypes. RNA-seq transcriptome profiling was conducted to uncover signaling and metabolic pathways perturbed by IFIT3 overexpression, and mitochondrial functional assays were performed to validate bioinformatic predictions.ResultsWe quantified 999 total CENPA-proximal proteins via label-free proteomics, identifying 32 DAPs in DSACs relative to NACs (19 upregulated, 13 downregulated). Enrichment analyses revealed robust dysregulation of interferon response and ribosomal protein networks in DSACs, with IFIT3 exhibiting the most significant upregulation. Lentiviral IFIT3-OE in pluripotent hiPSCs triggered G1-phase cell cycle arrest, suppressed cell proliferation, and elevated apoptotic rates. Transcriptome-wide RNA-seq demonstrated strong transcriptional repression of oxidative phosphorylation and mitochondrial ATP biogenesis gene sets, accompanied by direct functional deficits including reduced mitochondrial membrane potential and lowered intracellular ATP levels.ConclusionThis study identifies IFIT3 as a highly dysregulated CENPA-proximal candidate protein in fetal DS amniocytes. Gain-of-function assays in hiPSCs confirm that elevated IFIT3 expression is sufficient to disrupt mitochondrial homeostasis and recapitulate core DS cellular defects. Our work provides a novel proteomic framework linking centromere-proximal signaling to mitochondrial dysfunction in trisomy 21, and highlights IFIT3 as a candidate mediator of DS pathogenesis.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1967034</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1967034</link>
        <title><![CDATA[Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Lu-lu Xin</author><author>Jin-jin Guo</author><author>Xin-ying Zheng</author><author>Zhao-yang Li</author>
        <description><![CDATA[BackgroundSurgical trauma is associated with perioperative immune perturbation in muscle-invasive bladder cancer (MIBC). Enhanced Recovery After Surgery (ERAS) combines multidisciplinary perioperative management with structured nursing care, but its immunogenomic associations remain incompletely characterized.MethodsThis retrospective historical-control cohort included 126 MIBC patients undergoing radical cystectomy with Bricker ileal conduit (ERAS-based care, n = 63; conventional care, n = 63). Serial peripheral immune profiling was performed at T0 (preoperative), T1 (24 h postoperative), and T2 (POD7/discharge). Tumor analyses included multiplex immunofluorescence, tumor mutational burden (TMB), and NanoString immune-gene profiling; spatial transcriptomics was performed in 24 specimens (12/group). Clinical outcomes included 30-day infectious complications and survival, while biomarker and immunogenomic analyses were considered exploratory.ResultsERAS-based care was associated with a less pronounced postoperative CD8+ T-cell decline (22.8% vs. 41.6%, P < 0.001) and lower T1 serum IL-6 (43.2 vs. 87.4 pg/mL, P < 0.001). An exploratory four-marker T1 immune index (CD8+ count, IL-6, sPD-L1, and NK activity) showed predictive performance for 30-day infectious complications (AUC = 0.84, 95% CI 0.76–0.92). In resection specimens, the ERAS cohort had a higher proportion of the immune-inflamed tumor immune microenvironment (TIME) phenotype (52.4% vs. 28.6%, P = 0.012). Exploratory survival analyses also identified associations with an eight-gene immune signature and TMB status; these findings require validation.ConclusionIn this retrospective cohort, ERAS-based perioperative nursing and multidisciplinary care were associated with differences in systemic immune recovery, postoperative outcomes, and cross-sectional tumor immune features. The proposed immune-marker and gene-signature findings are exploratory and require independent validation before clinical implementation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1944709</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1944709</link>
        <title><![CDATA[The immunogenicity control axis: a multi-omics framework for integrating epigenetic, DNA damage response, and immune states in cancer]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Hypothesis and Theory</category>
        <author>Manyata Srivastava</author><author>Shishir Singh</author><author>Diksha Ameta</author><author>Aesha Singh</author><author>Monisha Banerjee</author><author>Atar Singh Kushwah</author>
        <description><![CDATA[Immunotherapy has transformed cancer treatment, yet therapeutic responses remain heterogeneous and are incompletely explained by immune-centric biomarkers alone. We propose the Immunogenicity Control Axis (ICA), a testable multi-omics framework integrating three complementary dimensions of tumor state: epigenetic regulation, DNA damage response (DDR), and immune activity. The central hypothesis is that epigenetic permissiveness influences immune-relevant transcription and antigen presentation, while DDR-associated genomic processes contribute to antigenic variation; together, these tumor-intrinsic features interact with the immune state to shape tumor immune visibility. To make this hypothesis quantitatively testable, the ICA is operationalized through independently derived Epigenetic, DDR, and Immune scores that are standardized and integrated into a composite ICA Score. Using cervical cancer as an initial disease context, patient-derived TCGA-CESC analyses provide exploratory assessment of ICA-associated molecular states and prognostic relationships, while synthetic analyses are used separately to illustrate specific analytical procedures. The framework is further extended to perturbational analysis, in which CMap/LINCS transcriptional signatures and network information are used to prioritize candidate natural compounds predicted to oppose ICA-associated molecular states. These computational analyses are intended as hypothesis-generating operationalizations rather than biological or clinical validation. ICA therefore provides a falsifiable framework for testing whether coordinated epigenetic, DDR, and immune information captures tumor immunogenic variation beyond individual molecular dimensions and for prioritizing perturbational hypotheses for subsequent experimental validation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1952672</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1952672</link>
        <title><![CDATA[More than one and less than many: research and care in pediatric first-in-human cell and gene therapy clinical trials]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Stanislav Birko</author><author>Ma’n H. Zawati</author>
        <description><![CDATA[The pediatric context poses specific challenges to the clinical translation of cell and gene therapies. We conducted a narrative review of literature addressing the responsibilities of researcher-clinicians in the context of clinical trials using cell and gene therapies, with an emphasis on first-in-human trials in minors. The inclusion criteria of our search yielded 16 papers, one of them addressing the exact intersection we were looking at, with the others circling this intersection. Only one of these 16 papers make a link to the wider theoretical debate on the tension between fulfilling the aims of clinical care and the aims of clinical research when conducting clinical trials–what is often referred to as the similarity vs. difference debate–and this debate’s connection to discussions of the central concept of the therapeutic misconception. Building on others’ claim that the similarity vs. difference framing is too simplistic to capture real-world nuance, we note that the concepts of therapeutic misconception and clinical equipoise both depend on mutually exclusive positions in this debate. We do not argue for jettisoning either of these concepts. Instead, we consider the resulting paradox to be productive. It is productive to integrate discussions of the therapeutic misconception and clinical equipoise into the similarity vs. difference debate, as the limitations of these discussions become more apparent in conjunction. In other words, researcher-clinicians taking their ethical duties seriously do not need to ‘solve’ these debates, but neither should this free them from engaging with the debates. Additionally, we discuss the legal context of cell and gene therapies in North America, concluding that nothing in the surveyed ethical literature suggests that greater uncertainties inherent in the field of early-phase cell or gene therapy trials justify relaxation of standards around informed consent for cell and gene therapy clinical trials.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1973772</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1973772</link>
        <title><![CDATA[GERBase: an online tool for high-resolution HLA allele and haplotype frequencies and linkage disequilibrium analysis in a Brazilian population]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Jose Samuel da Silva</author><author>Gustavo Vinicius Alves</author><author>Joao Henrique Coelho Campos</author><author>Gisele Fabianne Rampim</author><author>Alberto Cardoso Martins Lima</author><author>Maria Gerbase-DeLima</author><author>Renato de Marco</author>
        <description><![CDATA[GERBase is a web tool that provides family-phased, high-resolution Human Leukocyte Antigen (HLA) allele and haplotype frequencies together with linkage disequilibrium (LD) metrics. The tool supports haplotype blocks defined by the user’s query, as well as stratification by self-reported race or visualization of the total admixed population. For analysis, HLA alleles were grouped by antigen recognition domain (ARD), while the web tool retained the ability to discriminate between alleles within the same group. The database contains 17,260 haplotypes from unrelated candidates for hematopoietic cell or kidney transplantation, typed at IGEN (São Paulo, Brazil), phased by segregation analysis in family studies rather than statistically inferred; 9,026 haplotypes (52.3%) are phased across all nine classical loci, and the remainder across at least two. Allele frequencies in GERBase closely track those reported for the Brazilian donor registry in the Common, Intermediate, and Well-Documented (CIWD)-Brazil catalog (r = 0.9988; P < 0.0001 across 238 alleles). This tool can be used in the daily practice of HLA laboratories, including the investigation of allele dropout, the optimization of virtual crossmatching when donor HLA typing is incomplete, and the enhancement of donor prioritization for allogeneic hematopoietic cell transplantation. GERBase is available at https://www.igen.org.br/gerbase/, does not require registration and is free to use.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1916595</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1916595</link>
        <title><![CDATA[Donor-aware multi-cohort single-cell analysis identifies an LXR-linked tubular cholesterol-handling state in membranous nephropathy with a coordinated five-gene lipid-remodeling signature across renal tumors]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Yalan Mao</author><author>Ran Li</author><author>Bin Li</author><author>Hongfen Pan</author>
        <description><![CDATA[BackgroundMembranous nephropathy (MN) is an immune-mediated glomerular disease in which sustained proteinuria exposes renal tubular epithelial cells to an abnormal filtered-protein load. The tubular metabolic response to this exposure remains incompletely characterized. We investigated whether MN is associated with a reproducible tubular cholesterol-handling transcriptional state and assessed its relationship to protein overload in vitro. We further evaluated whether an experimentally anchored five-gene subset showed a coordinated tumor-associated transcriptional shift across major renal cancer histologies.MethodsThree kidney single-cell RNA-sequencing datasets and one glomerular bulk-transcriptomic cohort were analyzed using the donor as the biological replicate. GSE241302 was used for complete-case exploratory discovery, OEP004186 for formal donor-aware support, GSE171458 for directional support, and GSE200828 for tissue-level disease context. A frozen 47-gene LXR-linked cholesterol-handling program and its nested 37-gene cholesterol transport/efflux component were evaluated by donor-level pseudobulk analysis, leave-one-donor-out and leave-one-gene-out sensitivity analyses. HK-2 cells were exposed to protein overload, followed by quantitative reverse-transcription PCR for representative transport and lipid-remodeling genes. The same experimentally anchored five-gene panel was then evaluated in 129 paired tumor–adjacent-normal samples across TCGA-KIRC, TCGA-KIRP, and TCGA-KICH to define a renal tumor-associated lipid-remodeling context.ResultsAcross all 3 MN donors in GSE241302, program scores were higher than the internal reference in proximal tubule (PT) and loop-of-Henle/thick ascending limb (loop/TAL) compartments. In OEP004186, the program was increased in PT (effect +0.480, false-discovery rate [FDR] 0.0128), PT-VCAM1 (+0.348, FDR 0.0165), and loop/distal epithelial cells (+0.310, FDR 0.0242), with positive effects in every leave-one-MN-donor-out analysis. GSE171458 provided concordant directional support in PT and loop/TAL. The PT-VCAM1 fraction was not increased in MN, whereas the program remained higher within both PT and PT-VCAM1, favoring a within-state transcriptional change. Sixteen program genes showed positive average effects across the three single-cell resources. In GSE200828, the overall program was higher in MN than in living donors (+0.226, FDR 0.0349) but not higher than in other glomerular diseases. Protein overload increased ABCA1, ABCG1, SREBF1, FASN, and SCD expression in HK-2 cells. Across the three renal cancer histologies, the five-gene panel showed a concordant paired increase (REML-pooled effect +0.967, 95% CI 0.843–1.092), and 85.3% of patients exhibited simultaneous increases in the cholesterol-efflux and lipid-synthesis/remodeling arms.ConclusionMN is associated with a donor-supported LXR-linked cholesterol-handling transcriptional state concentrated in PT and loop/TAL-related epithelial compartments. The state is responsive to protein overload in HK-2 cells and may reflect a broader tubular lipid-homeostasis response to proteinuric kidney injury. The data do not establish direct LXR activation, increased cholesterol-efflux flux, or MN specificity. The paired renal cancer analysis further identifies a coordinated tumor-associated five-gene lipid-remodeling signature across KIRC, KIRP, and KICH, while not establishing tumor-cell-intrinsic LXR activation, immune effects, or a causal tumor mechanism.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fgene.2026.1938741</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fgene.2026.1938741</link>
        <title><![CDATA[Case Report: Prenatal diagnosis of congenital knee dislocation caused by BICD2 gene variant]]></title>
        <pubdate>2026-10-14T00:00:00Z</pubdate>
        <category>Case Report</category>
        <author>Xiaohua Ge</author><author>Wencong Li</author><author>Hong Wei</author><author>Meijuan Liu</author>
        <description><![CDATA[Congenital dislocation of the knee (CDK) is a rare malformation that severely affects the quality of life of affected fetuses and imposes a heavy burden on families and society. Its etiology remains unclear and may be related to genetic factors, quadriceps atrophy, muscular nutritional imbalance, and intrauterine factors. Here we report a case of CDK diagnosed prenatally by ultrasound in a 34-year-old pregnant woman at 25 weeks of gestation. Prenatal ultrasonography revealed knee hyperextension, abnormal hand morphology, and micrognathia. Exome sequencing identified a heterozygous mutation c.1613A>G (p.Tyr538Cys) in the BICD2 gene in the fetus, which was classified as likely pathogenic (PS2+PM2) according to American College of Medical Genetics and Genomics (ACMG) criteria. This variant is associated with autosomal dominant spinal muscular atrophy with lower extremity predominance type 2 (SMALED2). The prenatal ultrasound diagnosis was confirmed by autopsy after termination of pregnancy. This case expands the prenatal phenotypic spectrum of BICD2-related disorders by detailing the ultrasound features of CDK, highlights the diagnostic value of exome sequencing when fetal anomalies are detected prenatally, and is of great significance for the diagnosis of fetal congenital anomalies and the formulation of clinical management plans.]]></description>
      </item>
      </channel>
    </rss>